SecBot SecBot
8-K ·Filed Apr 23, 2026

DAWN

Day One Biopharmaceuticals, Inc.
NEUTRAL
Impact 9/10
Horizonimmediate Processed6mo ago SEC0001193125-26-171997
8-K material event: Items 1.02, 2.01, 5.01
Actionable Insight • Neutral

The stock will cease trading and shareholders have received cash proceeds. Monitor Servier's pipeline integration for potential future value in related biotech holdings.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK AT ENTRY AT T+1
Entry
$21.53
T+0 close · Apr 23, 2026 · via day close
Latest settled
0.00%
T+1 · $21.53
Vs SPY
−0.78%
α at T+1
Next horizon
T+5
due 7mo ago
  1. T+0 · Apr 23 $21.53entry
  2. T+1 · 7mo ago 0.00%α −0.78% · $21.53
  3. T+5 · due 7mo ago Pending
  4. T+20 · due 6mo ago Pending
  5. T+60 · due 4mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Day One Biopharmaceuticals (DAWN) was acquired by Servier Pharmaceuticals in an all-cash transaction valued at $2.5 billion, resulting in delisting from Nasdaq and termination of all existing equity plans. The merger closed after Servier secured 85.34% of shares in a tender offer.

Key Facts

  • Servier Pharmaceuticals completed acquisition of Day One Biopharmaceuticals for $2.5 billion in equity value
  • All outstanding shares converted to $21.50 in cash per share
  • Company delisted from Nasdaq following merger completion
  • Board and officers replaced with Servier appointees
  • All equity incentive plans terminated

Financial Impact

Total equity value of $2.5 billion paid in cash to shareholders

marketCapliquidityequityValue

Risk Factors

  • Loss of public market liquidity for former DAWN shareholders
  • Integration risk of Day One's pipeline into Servier's portfolio

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-171997
Document: d27888dex32.htm0001193125-26-171997
Document: d27888dex31.htm0001193125-26-171997
Document: 0001193125-26-171997-index-headers.html0001193125-26-171997
Document: 0001193125-26-171997-index.html0001193125-26-171997
Document: 0001193125-26-171997.txt0001193125-26-171997

Track record

6 reports on DAWN

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. May 4, 202628w ago 15-12G Neutral 5/10 No price data
  2. Apr 23, 202629w ago 25-NSE Neutral 9/10 Entry $21.53 No price data
  3. Apr 23, 202629w ago 8-K Neutral 9/10 Viewing Entry $21.53 No price data
  4. Apr 17, 202630w ago 10-K/A Neutral 4/10 Entry $21.48 No price data
  5. Mar 6, 202636w ago Press Release Bullish 9/10 Entry $21.20 to $21.46 ▲ +1.23% +3.27% vs SPY
  6. Feb 24, 202637w ago 8-K Bullish 8/10 Entry $10.92 to $21.37 ▲ +95.79% +101.02% vs SPY
Showing 6 of 6

US Market Status

Market Closed · Opens in 6h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 23, 2026